Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells $942,000.00 in Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $4.71, for a total transaction of $942,000.00. Following the completion of the sale, the insider owned 1,006,439 shares of the company’s stock, valued at $4,740,327.69. The trade was a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Sukumar Nagendran also recently made the following trade(s):

• On Friday, November 28th, Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.75, for a total transaction of $523,093.75.
• On Monday, December 1st, Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97.

Taysha Gene Therapies Stock Up 2.9%

NASDAQ:TSHA traded up $0.14 on Wednesday, hitting $5.04. The stock had a trading volume of 2,323,955 shares, compared to its average volume of 2,890,317. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies, Inc. has a 52 week low of $1.05 and a 52 week high of $6.02. The business’s fifty day moving average is $4.95 and its 200 day moving average is $3.92. The company has a market cap of $1.38 billion, a PE ratio of -15.27 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. On average, equities research analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Institutional Trading of Taysha Gene Therapies

Several hedge funds have recently made changes to their positions in the company. Marex Group plc bought a new stake in Taysha Gene Therapies in the 2nd quarter valued at about $29,000. E Fund Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter valued at approximately $31,000. ST Germain D J Co. Inc. raised its holdings in Taysha Gene Therapies by 81.8% during the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after acquiring an additional 4,333 shares during the period. May Hill Capital LLC purchased a new position in shares of Taysha Gene Therapies in the second quarter valued at $37,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in Taysha Gene Therapies in the 3rd quarter worth about $40,000. 77.70% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TSHA has been the subject of several recent research reports. UBS Group set a $11.00 price target on Taysha Gene Therapies in a report on Thursday, December 4th. Wall Street Zen downgraded Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. Citizens Jmp upped their price objective on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “market outperform” rating in a research note on Wednesday, November 5th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $13.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.67.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.